<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: The present study aimed to explore the impact of the angiotensin type 1 receptor blocker <z:chebi fb="0" ids="9927">valsartan</z:chebi> (VAL) on inflammatory-/<z:chebi fb="23" ids="18059">lipid</z:chebi>-/<z:chebi fb="105" ids="17234">glucose</z:chebi> parameters in hypertensive diabetic patients with and without <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> (CAD) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This was a 16-week, randomized, double-blind, placebo-controlled two-center study with VAL 320 mg/d in 109 hypertensive diabetic patients (n=56 non-CAD; n=53 CAD) </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: VAL treatment did not significantly affect serum interleukin-6 (IL-6) or <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha (TNFalpha) levels in the overall study population but significantly reduced serum IL-6 in the subgroup with high inflammatory load at baseline (IL-6&gt;median (2.0 ng/L), n=54: [median, ng/L]): VAL: from 3.5 to 2.4; placebo: from 3.2 to 3.5; p=0.035) </plain></SENT>
<SENT sid="3" pm="."><plain>VAL significantly lowered total- and <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> in the whole study population: [median, mg/dL]: total cholesterol: VAL: from 178 to 168; placebo: from 174 to 173, p=0.039; <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi>: VAL: from 96 to 90, placebo: from 102 to 103, p=0.006, whereas glycemic parameters were not affected </plain></SENT>
<SENT sid="4" pm="."><plain>CONCLUSIONS: The present study demonstrates significant anti-inflammatory efficacy of VAL in hypertensive diabetic patients with enhanced inflammatory burden </plain></SENT>
<SENT sid="5" pm="."><plain>High-dose VAL therapy significantly lowered total- and <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> levels </plain></SENT>
<SENT sid="6" pm="."><plain>The combined actions of cholesterol and blood pressure lowering by VAL may provide additional clinical benefits for these high-risk patients </plain></SENT>
</text></document>